JRNYS is a comprehensive telehealth platform that provides medically supervised weight loss programs centered on GLP-1 medications like Semaglutide and Tirzepatide.

Converts on purchase (program subscription/medication order).

Targeting: Adults in the US aged 25–55 with a BMI over 30 (or 27 with weight-related health issues) who are seeking medical intervention for weight management. Appeals to individuals who have found traditional diet and exercise insufficient and those looking for a legitimate, clinical path to GLP-1 therapy.

Restrictions: No brand bidding, coupon sites, or Buy Now Pay Later partners allowed. No social traffic from Meta. All creatives and copy must be FDA-compliant and pulled from pre-approved assets.

All assets